Apricus Biosciences (APRI) Getting Somewhat Favorable News Coverage, Report Finds

News headlines about Apricus Biosciences (NASDAQ:APRI) have trended somewhat positive on Monday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Apricus Biosciences earned a coverage optimism score of 0.01 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.6543863763339 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media headlines that may have impacted Accern’s scoring:

How to Become a New Pot Stock Millionaire

Shares of APRI stock remained flat at $$0.38 during trading hours on Monday. 1,270,829 shares of the stock traded hands, compared to its average volume of 1,348,741. Apricus Biosciences has a 1 year low of $0.36 and a 1 year high of $3.34. The stock has a market capitalization of $8.44, a price-to-earnings ratio of -0.38 and a beta of 1.35.

Apricus Biosciences (NASDAQ:APRI) last released its earnings results on Thursday, March 1st. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.01). During the same quarter in the previous year, the firm posted $0.03 EPS. equities research analysts anticipate that Apricus Biosciences will post -0.4 earnings per share for the current year.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Apricus Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 3rd. HC Wainwright lowered shares of Apricus Biosciences from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a report on Friday, February 16th. Finally, ValuEngine upgraded shares of Apricus Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3344184/apricus-biosciences-apri-getting-somewhat-favorable-news-coverage-report-finds.html.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc, a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma.

Insider Buying and Selling by Quarter for Apricus Biosciences (NASDAQ:APRI)

Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Walmart Inc  Shares Sold by Van Hulzen Asset Management LLC
Walmart Inc Shares Sold by Van Hulzen Asset Management LLC
Microsoft Co.  Shares Bought by UMB Bank N A MO
Microsoft Co. Shares Bought by UMB Bank N A MO
Two Sigma Investments LP Has $662,000 Stake in UMH Properties, Inc.
Two Sigma Investments LP Has $662,000 Stake in UMH Properties, Inc.
16,211 Shares in American Railcar Industries  Acquired by Two Sigma Investments LP
16,211 Shares in American Railcar Industries Acquired by Two Sigma Investments LP
Venator Materials  Stake Increased by Two Sigma Advisers LP
Venator Materials Stake Increased by Two Sigma Advisers LP
Hunters Property  Announces Dividend of GBX 1.50
Hunters Property Announces Dividend of GBX 1.50


Leave a Reply

© 2006-2018 Ticker Report. Google+.